Thromboxane A2 (TxA2) is a potent platelet agonist that serves as an amplifying signal after exposure of platelets to other stimulants, such as thrombin, in vitro. Exposure of platelets to the TxA2 receptor agonists U46619 and SQ 26,655 (1.4 ,AM) resulted in a 60-90% decrease in subsequent TxA2 receptor-stimulated aggregation, calcium release, and protein kinase C activation. The desensitization was rapid, with a half-time of 2-3 min. The sequence of events involved in TxA2 receptor desensitization involves initial uncoupling of the receptor from a guanine nucleotide binding (G) protein followed by eventual receptor down-regulation. Consistent with this hypothesis were (i) a 60-70% decrease in SQ 26,655-stimulated platelet GTPase activity, (ii) a shift to the right ofthe dose-response curve for U46619-stimulated release of calcium [ECso, 275 ± 51 nM (control)] vs. 475 ± 71 nM (desensitized); P < 0.01], and (iii) a delayed loss ofreceptor sites. In summary, exposure of platelets to TxA2 receptor agonists results in rapid desensitization of the biochemical and functional responses to interaction with its receptor in human platelets. The kinetics of these events are consistent with the hypothesis that this icosanoid functions in the regulation as well as amplification of platelet activation in vivo.
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Thromboxane A2 (TxA2) is a potent agonist of platelet activation, causing shape change, secretion, and aggregation (1) . TxA2 is also an important potentiator of platelet activation by other platelet stimulants, such as ADP and epinephrine. These agents stimulate the release and subsequent metabolism to TxA2 of arachidonic acid (2, 3) . TxA2, largely derived from platelets, is synthesized in vivo even under physiological conditions (4) , implying continuous platelet activation, which would seem likely to be subject to regulatory constraints. One potential mechanism whereby platelet function might be controlled would be the decreased response of platelets to TxA2 after exposure to agonist, or desensitization.
We have characterized the molecular events involved in TxA2 receptor desensitization by comparing the biochemical responses to TxA2 receptor stimulation in untreated and desensitized platelets. Our results indicate that desensitization of platelet TxA2 receptors is mediated initially by impaired coupling between the TxA2 receptor and its second messenger system-guanine nucleotide binding (G) proteincoupled phospholipase C activation. Uncoupling of receptor stimulation from phospholipase C activation is followed, upon extended exposure to agonist, by a decrease in platelet TxA2 receptor density.
MATERIALS AND METHODS Materials. 9,11-Dimethylmethano-11,12-methano-16-(4-hydroxyphenyl)-13,14-dihydro-13-aza-15-al8w-tetranor- -(epoxymethano)prosta-5Z,13E-dienoic acid (U46619) was a gift from R. Gorman (Upjohn, Kalamazoo, MI). Reagents for polyacrylamide gel electrophoresis were from Bio-Rad. Other reagents were from Sigma except where indicated otherwise.
Desensitization and Preparation of Washed Platelets. Blood was drawn from healthy human volunteers (who had not taken any medication for at least 10 days) by venipuncture into EDTA (5 mM) and indomethacin (5 Iug/ml) (final concentrations). The blood was centrifuged for 10 min at 160
x g, and platelet-rich plasma (PRP) was removed. For desensitization, PRP was incubated at room temperature for 30 min (or as indicated in individual experiments) with the TxA2 receptor agonists U46619 (1.4 ,uM) (5), SQ 26,655 (1.4 ,uM) (6), or vehicle (control). The platelets were washed as described (7) . All buffers contained indomethacin at 5 ,ug/ml. Platelet Aggregation. Platelets (0.5 ml; -108 platelets per ml) were preincubated at 37°C for 2 min, then stimulant was added, and the extent of aggregation was monitored by light transmission in a Biodata Pap 4 aggregometer.
Calcium Measurement. Intracellular free calcium (Ca2+) measurements were made by monitoring the intensity of fura-2 fluorescence. PRP was incubated with 1 ,uM fura-2 AM (Molecular Probes) at 37°C for 30 min. The fura-2-loaded platelets were desensitized and washed as described above. Changes in fluorescence of the fura-2-loaded platelets at excitation wavelengths of 340 and 380 nm (less autofluorescence of the platelets in the absence of fura-2 loading) after addition of various agonists were recorded. The ratio of fluorescence at excitation wavelength 340 nm to fluorescence at excitation wavelength 380 nm (relative fluorescence intensity) is a measure of Ca71' concentration (8) .
Phosphorylation of 47-kDa Protein. Phosphorylation of platelet 47-kDa protein, a protein kinase C substrate, was assessed as described (9) . After two washes in phosphate-free buffer, control and desensitized platelets were resuspended to a concentration of 2 x 109 platelets per ml in the same buffer [15 mM Tris-HCl, pH 7.4/150 mM NaCl/5 mM dextrose/indomethacin (5 Incubations were done in duplicate at 370C for 30 min. The reaction was terminated by dilution with 4 ml of ice-cold 10 mM Tris HCl (pH 7.4) and the reaction mixture was immediately filtered through Whatman GF/C glass fiber filters (Fisher). The filters were then washed with an additional 3 x 4 ml of 10 mM Tris HCl buffer.
Competition binding. 3H-SQ 29,548 (0.5 nM) was incubated with -5 x 107 platelets in the presence of various concentrations (1 nM to 10 AM) of U46619 or PTA-OH in binding buffer in a total volume of 200 ,ul. Incubations were done in duplicate at 37°C for 30 min and were terminated as described for saturation binding assays. After addition of 10 ml of scintillation fluid, the filters were assayed by liquid scintillation counting.
Binding analyses were performed by computerized nonlinear curve fitting using the LIGAND program, as described by Munson and Robard (12) .
GTPase Assays. Stimulation of platelet high-affinity GTPase activity was assessed as an indication of receptor-G protein coupling (13) . Platelet membranes were prepared, following desensitization, as described (14) . GTPase activity was measured essentially by the method of Cassel and Selinger (15) . High-affinity GTPase activity was defined as that inhibited by the inclusion of 1 mM GTP in the assay. Each point was measured in triplicate with and without 1 mM GTP. After incubation for 10 min at 37°C, 1 ml of ice-cold 5% charcoal (Norit A) in 20 mM phosphate (pH 7.5) was added, and the mixture was vortexed and centrifuged at 3000 rpm for 5 min in a Beckman Microfuge. Aliquots (200, ul) were assayed by liquid scintillation counting. A blank value was obtained in the absence of added platelet membranes and always represented 2-5% of total [32P]GTP added.
Statistical Analysis. Pairwise comparisons were performed by the Student's t test. RESULTS TxA2 Receptor Desensitization. Platelets preincubated with either of the TxA2 receptor agonists (U46619 or SQ 26, 655) were 60-70% less responsive to a subsequent stimulus with either agonist, as measured by the aggregation response. Occasionally, full desensitization was observed (an example is shown in Fig. 2 ). Thrombin (0.1 unit/ml)-stimulated aggregation was slightly decreased (by 10%) by preincubation with either TxA2 mimetic (the decrease in thrombin stimulation was significantly less than TxA2 receptor agonist desensitization; P < 0.001) (Fig. 1A) . The onset of desensitization was rapid-desensitization was maximal by 15 (Fig. 1B) .
The specificity of the induction of desensitization by interaction of the TxA2 receptor agonists with the TxA2 receptor was demonstrated by the inhibition of the induction of desensitization in the presence of the TxA2 receptor antagonist SQ 29,548 (Fig. 2) .
Platelet aggregation has been associated with activation of phospholipase C, with resultant production of inositol trisphosphate and 1,2-diacylglycerol, which stimulate release of Ca2' and the activation of protein kinase C, respectively.
Resting Caj2+ concentrations were identical in control and desensitized platelets (0.68 ± 0.01 and 0.65 ± 0.03 fluorescence units, respectively). U46619 (1 MM) time points (Fig. 6 ). After desensitization for 24 hr, the receptor density had decreased to 50o of control (control receptor number was 263 ± 27 fmol per 108 platelets).
Heterologous Desensitization of the TxA2 Receptor. While exposure of platelets to TxA2 receptor agonists only slightly decreased the subsequent stimulation of aggregation by thrombin, pretreatment of EDTA anticoagulated PRP with thrombin (0.15 unit/ml) reduced the subsequent aggregation responsiveness of the platelets to stimulation by U46619 to 39% ± 8% of control aggregation (n = 4).
DISCUSSION
This study was designed to explore the mechanisms involved in regulation of the platelet TxA2 receptor after exposure to TxA2 receptor agonists. Carmo et al. (20) reported U46619 and arachidonic acid-induced cross-desensitization of the platelet aggregation response. This observation has been confirmed and extended to include desensitization induced by a structurally distinct TxA2 receptor agonist, SQ 26,655. The induction of desensitization in EDTA-anticoagulated PRP demonstrates that aggregation is not necessary for desensitization to occur and removes the necessity of prostacyclin addition, preventing any possible contribution to or inhibition of desensitization by elevated cyclic AMP (21) .
Platelet biochemical responses (Ca?+ release and 47-kDa protein phosphorylation) were correlated with changes in the aggregation response after desensitization. The stimulation of all three parameters by TxA2 receptor agonists was decreased by at least 60%o after desensitization. Although thrombin stimulation of aggregation and Ca1?' stimulation by thrombin were slightly decreased (by 10% + 4% and 27% ± 6%, respectively) in desensitized platelets, the decreased responsiveness to thrombin was significantly less (P < 0.001) than to the TxA2 receptor agonists. It is important to note that, although in vivo thrombin stimulation is thought to be potentiated by release of TxA2, the decrease in thrombin stimulation of aggregation and Caj2+ release observed in our experiments was not due to a desensitization of the TxA2 contribution to stimulation-all of the experiments reported here were performed in the presence of indomethacin at concentrations that inhibit the production of endogenous TxA2 (22) .
The rapid kinetics of desensitization are consistent with a functional role for this process in regulating the effects of this evanescent (t.2, =30 sec) platelet agonist in vivo. The platelets remained desensitized for at least 1 hr (data not shown).
The sequence of events thought to be involved in homologous desensitization of the B3-adrenergic receptor has been extensively defined (23) . In the continued presence of agonist, the fi-adrenergic receptor is rapidly phosphorylatedthe receptor becomes uncoupled from Gs and, therefore, from the adenylate cyclase enzyme. The receptor is then sequestered from the membrane surface and ultimately down-regulated, or converted to a form that can no longer bind radioligands and is not detectable by immunofluorescence (24) . We have made several observations consistent with a similar sequence of events during TxA2 receptor desensitization.
TxA2 receptor stimulation has been shown to be mediated by a G protein-in permeabilized platelets, U46619-induced phosphatidic acid production and secretion were inhibited by the G protein inhibitor GDP[/3S] (25) . Stimulation of a high-affinity GTPase by TxA2 receptor agonists (U46619 and U44069) has also been demonstrated (26, 27) . We assessed TxA2 receptor stimulation of GTPase activity as a measure of receptor-G protein coupling in control and desensitized platelets. After 30 min to 1 hr of desensitization, there was little change in TxA2 receptor properties-no change in affinity for agonist and no loss of 3H-SQ 29,548 binding sites. There was, however, a 60% reduction in GTPase stimulation by SQ 26,655, consistent with a loss of TxA2 receptor-G protein coupling. Thrombin stimulation of GTPase activity was unchanged in desensitized platelets, suggesting that either the small (10-30%) decrease in aggregation and Ca2+ responsiveness to thrombin stimulation in desensitized platelets is not mediated by a change in thrombin receptor activation, or that the GTPase assay was not sensitive enough to detect a small change in thrombin-stimulated GTPase activity. Since the TxA2 receptor and the thrombin receptor appear to couple to distinct G proteins (25) , it is not clear whether the locus of the modification responsible for impaired TxA2 receptor-G protein coupling is the TxA2 receptor or the G protein.
The dose-response curves in control and desensitized platelets for U46619 stimulation of Ca2+ release also suggest that uncoupling of the TxA2 receptor from phospholipase C is the first stage in its desensitization-the EC50 for U46619 was increased in desensitized platelets and may indicate an uncoupling of receptor compared to control.
After 1 hr of desensitization, there was a 20-30% decrease in TxA2 receptor number using the radioligand 15I-PTA-OH to measure binding. This receptor down-regulation was not observed when the radioligand 3H-SQ 29,548 was used. While it could be argued that the difference in 125I-PTA-OH and 3H-SQ 29,548 binding in desensitized platelets may be due to residual agonist, we feel this is unlikely. If U46619 or SQ 26,655 had been retained after washing and were not efficiently displaced by 125I-PTA-OH, we would expect to see a decrease in affinity for the ligand. In fact, there was no change in affinity for 1251-PTA-OH after desensitization (Kd = 23 + 2 nM in control and 16 + 2 nM in desensitized platelets; P > 0.05). Heterogeneity in binding of TxA2 receptor radioligands has been a feature of platelet TxA2 receptor studies-there have been discrepancies in the sites labeled by 3H-U46619 and 125I-PTA-OH (28) . While the 3H-U46619 and 125I-PTA-OH site difference has been attributed to different properties of agonist and antagonist binding, there may be a more fundamental difference in the nature of the sites identified or in the relative specificity of the ligands used. Another indication of heterogeneity of platelet TxA2 receptor sites is the observation that the antagonist PTA-OH recognizes two affinity states of the receptor-states that are not discriminated by the other agonists and antagonists used in this study. One interpretation of the existence of two sites for PTA-OH and the relative decrease in the proportion of low-affinity sites following desensitization is that the low-and Biochemistry: Murray and FitzGerald 128 Biochemistry: Murray and FitzGerald high-affinity sites for PTA-OH represent coupled and uncoupled forms of the receptor, respectively. This is supported by the observation that the EC50 for U46619 stimulation of CaF+ release in control platelets is higher than the Kd for U46619 binding, suggesting that there are uncoupled or poorly coupled receptors in control platelets. After 30 min of desensitization, there is an increase in the proportion of uncoupled receptors (reflected in an increased EC50 for U46619 in desensitized platelets).
After the initial rapid uncoupling of TxA2 receptor and its associated G protein, there was, in the continued presence of agonist, a slow down-regulation of receptor, demonstrated by a 50% ± 8% loss in receptor number following 24 hr of desensitization, as measured using 3H-SQ 29,548. This longterm down-regulation of receptor number may have some clinical relevance; for example, in conditions associated with sustained augmentation of TxA2 biosynthesis, such as severe peripheral vascular disease (29) .
The TxA2 receptor was subject to heterologous desensitization following platelet exposure to thrombin, suggesting that refractoriness to TxA2 stimulation may be of general importance in regulating platelet activation by stimulants other than TxA2 itself.
Given the rapid amplification that occurs upon platelet stimulation due to release of arachidonic acid and its metabolism, an understanding of the regulation of the complex pathways of platelet activation is desirable. The rapid uncoupling of the TxA2 receptor upon exposure to TxA2 receptor agonists and subsequent down-regulation of receptor number and the heterologous desensitization of the TxA2 receptor by thrombin are consistent with the hypothesis that desensitization to TxA2 functions as an important element in the physiological control of platelet activation in vivo.
